General InformationNewLimit is a longevity biotechnology company headquartered in South San Francisco, CA, with 11–50 employees, founded in 2022 to develop epigenetic reprogramming medicines that extend human healthspan.
Funding & FinancialsNewLimit has raised approximately $247M+ in total funding, including a $130M Series B led by Kleiner Perkins in May 2025 and a subsequent $45M raise at a $1.62B valuation from investors including Eli Lilly, Duke Management Co., Khosla Ventures, and Founders Fund.
Leadership & TeamThe company was co-founded by Coinbase CEO Brian Armstrong, GV veteran Blake Byers, and scientist Jacob Kimmel, who serves as Co-founder and President overseeing research.
Recent ActivityIn late 2025, NewLimit selected its first preclinical lead mRNA payload for liver rejuvenation and announced plans to advance the candidate into human clinical trials, calling it among the first epigenetic reprogramming assets in the industry.